Abilify MyCite and innovating in digital healthpharmaphorum’s Paul Tunnah spoke with Otsuka Pharmaceutical’s North America Pharmaceutical Business president and CEO Kabir Nath about the Share XAbilify MyCite and innovating in digital healthhttps://pharmaphorum.com/views-analysis-digital/abilify-mycite-and-innovating-in-digital-health/
Building a new type of pharmaceutical company – a vision for pharma 2.0The definition of healthcare has become incredibly diverse since the turn of the century. It feels like it Share XBuilding a new type of pharmaceutical company – a vision for pharma 2.0https://pharmaphorum.com/views-analysis-sales-marketing/building-new-pharmaceutical-company-pharma-2-0/
Let’s talk about drugsPaul Tunnah asks if we need to rethink pharma’s strict marketing regulations and have a discussion on how Share XLet’s talk about drugshttps://pharmaphorum.com/views-and-analysis/lets-talk-drugs/
JP Morgan Healthcare: where science, tech and finance collideWelcome to 2019! Hopefully by now you’re managing to ease yourself back into things, no doubt with good Share XJP Morgan Healthcare: where science, tech and finance collidehttps://pharmaphorum.com/views-analysis-sales-marketing/jp-morgan-healthcare-science-tech-finance-collide/
Why pharma’s focus on patients requires less patienceHave you missed me? I certainly wouldn’t be so egotistical to assume that anyone has, but bizarrely it’s Share XWhy pharma’s focus on patients requires less patiencehttps://pharmaphorum.com/patients/pharmas-focus-patients-requires-less-patience/
Can ‘design thinking’ revolutionise pharma’s culture?As part of pharmaphorum’s ‘eye-on-innovation’ series, Paul Tunnah speaks to UCB’s head of innovation, Gregory Miller, about how Share XCan ‘design thinking’ revolutionise pharma’s culture?https://pharmaphorum.com/views-and-analysis/can-design-thinking-revolutionise-pharmas-culture/
Merck KGaA celebrates 350 years of innovationAs part of pharmaphorum’s eye-on-innovation interview series, Paul Tunnah speaks to Merck Biopharma’s vice president of innovation Ulrich Share XMerck KGaA celebrates 350 years of innovationhttps://pharmaphorum.com/views-analysis-digital/merck-kgaa-celebrates-350-years-innovation/
Innovation, endpoints and education – what’s in store for pharma in future-healthcare?As part of pharmaphorum’s ‘eye-on-innovation’ interview series, Paul Tunnah speaks to Bayer’s Chief Marketing Officer Pharmaceuticals, Sebastian Guth, Share XInnovation, endpoints and education – what’s in store for pharma in future-healthcare?https://pharmaphorum.com/views-and-analysis/innovation-endpoints-education-whats-store-pharma-future-healthcare/
Tackling the rare disease conundrum with passion, innovation and investmentThe first Cambridge Rare Disease Summit brought all stakeholders together to discuss the key issues and, in doing Share XTackling the rare disease conundrum with passion, innovation and investmenthttps://pharmaphorum.com/views-and-analysis/tackling-the-rare-disease-conundrum-with-passion-innovation-and-investment/
